Request Demo
Last update 10 Jun 2026
RGT-490
Last update 10 Jun 2026
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms- |
Target |
Action inhibitors |
Mechanism PI3Kα inhibitors(Phosphatidylinositol 3 kinase alpha inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
1
Clinical Trials associated with RGT-490NCT07524322
A Phase 1/1b Open-Label, Multicenter, First-in-Human Study Evaluating Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of RGT-490 as a Single Agent in Adult Subjects With Locally Advanced or Metastatic PIK3CA-Mutated Solid Tumors Including HR+/HER2- Breast Cancers
100 Clinical Results associated with RGT-490
Login to view more data
100 Translational Medicine associated with RGT-490
Login to view more data
100 Patents (Medical) associated with RGT-490
Login to view more data
100 Deals associated with RGT-490
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced breast cancer | Phase 1 | United States | 01 Jun 2026 | |
| Endometrial Carcinoma | Phase 1 | United States | 01 Jun 2026 | |
| HER2-negative breast cancer | Phase 1 | United States | 01 Jun 2026 | |
| Hormone receptor positive breast cancer | Phase 1 | United States | 01 Jun 2026 | |
| Locally Advanced Malignant Solid Neoplasm | Phase 1 | United States | 01 Jun 2026 | |
| Ovarian Cancer | Phase 1 | United States | 01 Jun 2026 | |
| Uterine Cervical Cancer | Phase 1 | United States | 01 Jun 2026 | |
| PIK3CA positive Solid Tumors | IND Approval | China | 04 Jun 2026 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free